At $841 billion market cap and 41x trailing earnings, Eli Lilly looks expensive by every traditional metric. But Mounjaro and Zepbound are creating a revenue trajectory that makes 41x look cheap in hindsight.
Eli Lilly trades at $940 per share, a market capitalisation of $841 billion, and a trailing P/E of 41.0x. By any conventional pharma valuation framework, the stock is expensive. The sector median is 14-16x. Even high-growth biotech rarely sustains multiples above 30x for more than a few quarters.
But Lilly isn't a conventional pharma company anymore. Mounjaro (tirzepatide) and Zepbound have created the first genuinely new pharmaceutical category in two decades — GLP-1 receptor agonists for obesity and diabetes. The addressable market for obesity drugs alone is estimated at $100-150 billion annually at maturity. Lilly and Novo Nordisk are the only two companies with approved products. That's a duopoly in a market that didn't exist five years ago.
At 41x trailing earnings, the market is pricing in strong growth. At $65.2 billion in 2025 revenue — up from $34.1 billion in 2023 — the growth is already arriving faster than consensus expected. The argument here is simple: the trailing multiple overstates the actual valuation because earnings are accelerating.
Strip out the noise and focus on the revenue trajectory. Lilly grew from $28.5 billion in 2022 to $65.2 billion in 2025 — a compound annual growth rate of 31.8%. No large-cap pharma company has sustained that pace in the modern era. Pfizer's COVID vaccine revenue, which briefly pushed growth rates above 90%, collapsed just as quickly. Lilly's growth is structural, not event-driven.
The operating margin of 44.9% tells you the GLP-1 franchise is dropping revenue to the bottom line at an extraordinary rate. The gross margin on Mounjaro and Zepbound is estimated at over 80%, which means each incremental dollar of revenue contributes disproportionately to operating income.
If Lilly sustains even half its current growth rate through 2027-2028 — reaching $90-100 billion in revenue — the trailing P/E at today's stock price drops to 25-28x. That's a premium to pharma but a discount to the growth rate. The PEG ratio, currently around 1.2x by our estimates, suggests the stock is fairly valued to slightly cheap relative to its growth trajectory.
The last time a pharma company experienced this kind of category-creating growth was Gilead Sciences with Sovaldi/Harvoni in 2013-2015. Gilead's stock tripled over that period before the market eventually priced in peak revenue. Lilly is earlier in its cycle, with a much larger addressable market.
TickerXray Report
Get the complete Eli Lilly report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
The bear case on Lilly is not about demand — it's about supply. Manufacturing GLP-1 drugs at scale requires specialised biologic production capacity that takes years to build. Lilly has invested billions in new manufacturing facilities, but capacity constraints have limited Mounjaro and Zepbound availability in multiple markets.
If Lilly can't meet demand, it loses share to Novo Nordisk's Ozempic and Wegovy. If it can meet demand, the revenue upside is substantially larger than current consensus estimates. This binary supply outcome is the primary risk factor, and it's the one we're least worried about. Lilly's track record on manufacturing execution is strong, and the capital expenditure commitment — visible in the annual capex numbers — demonstrates management's confidence in their capacity buildout.
The dividend yield of 0.63% is negligible, which is fine. You don't buy Lilly for income. You buy it because the obesity market is real, the addressable population is enormous, and Lilly has one of only two approved products serving that market.
At 41x trailing earnings, Eli Lilly appears expensive. At an estimated 28-30x forward earnings based on the GLP-1 revenue trajectory, it's reasonably valued. At our 2028 revenue estimate of $95-100 billion — which assumes supply constraints ease and market penetration continues — the current stock price implies a 20-22x earnings multiple. That's cheap for a company growing earnings at 30%+ annually.
We'd be adding to positions on any pullback to the $850-880 range, with a 12-month price target of $1,050-1,100. The catalyst path is straightforward: each quarterly earnings report that confirms the GLP-1 revenue ramp triggers another wave of consensus estimate upgrades, which supports the multiple. The risk is a manufacturing setback or a safety signal — either would cause a sharp de-rating. But absent those tail risks, the setup is as compelling as it gets in large-cap pharma.
Full forensic analysis of Eli Lilly
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The shift from injectable to oral delivery could expand the addressable GLP-1 market by 3-4x. Lilly's pharmacy partnerships make it a distribution play, not just a drug launch.
Revenue surged 38% to $65.2B in FY2025 as Mounjaro and Zepbound scaled. With manufacturing constraints easing and retatrutide data approaching, we're raising our revenue estimate to $90-100B by 2028.
Foundayo's FDA approval transforms Eli Lilly from an injectable GLP-1 leader into an oral mass-market platform, with revenue already at $65.2 billion and accelerating.